Prostanoid Receptor
Prostanoid receptors are activated by the endogenous ligands prostaglandin (PG) D2, PGE2, PGF2α , PGH2, prostacyclin (PGI2) and thromboxane A2. Cyclooxygenase (COX) converts arachidonic acid to PGH2, from which the other prostaglandins are synthesized.
Products for Prostanoid Receptor - Page 2
- Cat.No. Product Name Information/Activity
-
BCC7853
TCS 2510
346673-06-1
-
BCC7207
U 46619
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist.
-
BCC1332
AH 6809
AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.
-
BCC7961
GW 627368
GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor with additional human TP receptor affinity, with pKi values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.
-
BCC7393
L-161,982
L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice.
-
BCC7156
L-655,240
103253-15-2
-
BCC5857
L-670,596
121083-05-4
-
BCC7654
L-798,106
L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of 916 nM, >5000 nM and >5000 nM at EP4, EP1 and EP2, respectively.
-
BCC1822
ONO-AE3-208
High affinity and selective EP<sub>4</sub> antagonist,ONO-AE3-208 is an <b>EP4</b> antagonist, and suppresses cell invasion, migration, and metastasis of prostate cancer.
-
BCC6299
PF 04418948
PF-04418948 is an orally active, potent and selective prostaglandin EP2 receptor antagonist with an IC50 of 16 nM.
